# Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors

> **NCT03415659** · PHASE1 · UNKNOWN · sponsor: **Hubei Biological Medicine Industrial Technology Institute Co., Ltd.** · enrollment: 85 (estimated)

## Conditions studied

- Advanced Solid Tumors
- HRD
- BRCA Mutation

## Interventions

- **DRUG:** HWH340 tablet

## Key facts

- **NCT ID:** NCT03415659
- **Lead sponsor:** Hubei Biological Medicine Industrial Technology Institute Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-05
- **Primary completion:** 2021-03-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 85 (ESTIMATED)
- **Last updated:** 2020-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03415659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03415659, "Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03415659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*